{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-25-000050","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.732103+00:00","generated_at":"2026-05-21T17:06:33.449737+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Instil Bio Q1 net loss $4.32/share; restructuring charges $16.1M; cash $111.8M","bullets":["Net loss per share $4.32 (GAAP) vs $3.74 YoY; non-GAAP $1.32 vs $2.39.","Cash and investments $111.8M, down from $115.1M at Dec 31, 2024; runway beyond 2026.","Restructuring & impairment charges $16.1M vs $4.3M YoY; R&D $5.4M, G&A $9.1M.","AXN-2510/IMM2510 China trial ongoing; initial 1L NSCLC data expected 2H 2025.","U.S. clinical study of AXN-2510/IMM2510 in 1L NSCLC anticipated before end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-25-000050","json":"https://secwatch.observer/filing/0001789769-25-000050.json","markdown":"https://secwatch.observer/filing/0001789769-25-000050.md","text":"https://secwatch.observer/filing/0001789769-25-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000050/0001789769-25-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000050/til-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T17:06:33.449737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}